119 related articles for article (PubMed ID: 35385701)
1. Microbial metabolite as icebreaker for immunotherapy.
Tang Y; Kang Y
Cell Metab; 2022 Apr; 34(4):506-507. PubMed ID: 35385701
[TBL] [Abstract][Full Text] [Related]
2. The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer.
Wang H; Rong X; Zhao G; Zhou Y; Xiao Y; Ma D; Jin X; Wu Y; Yan Y; Yang H; Zhou Y; Qian M; Niu C; Hu X; Li DQ; Liu Q; Wen Y; Jiang YZ; Zhao C; Shao ZM
Cell Metab; 2022 Apr; 34(4):581-594.e8. PubMed ID: 35278352
[TBL] [Abstract][Full Text] [Related]
3. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.
Wu SY; Xiao Y; Wei JL; Xu XE; Jin X; Hu X; Li DQ; Jiang YZ; Shao ZM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321275
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in triple-negative breast cancer.
Katz H; Alsharedi M
Med Oncol; 2017 Dec; 35(1):13. PubMed ID: 29255938
[TBL] [Abstract][Full Text] [Related]
5. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
6. Different Triple-Negative Breast Cancer Tumor Cell Lysates (TCLs) Induce Discrepant Anti-Tumor Immunity by PD1/PDL-1 Interaction.
Dong B; Ding Y; Huang Q; Guan X
Med Sci Monit; 2019 Jan; 25():500-515. PubMed ID: 30653481
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
8. LXR-inverse agonism stimulates immune-mediated tumor destruction by enhancing CD8 T-cell activity in triple negative breast cancer.
Carpenter KJ; Valfort AC; Steinauer N; Chatterjee A; Abuirqeba S; Majidi S; Sengupta M; Di Paolo RJ; Shornick LP; Zhang J; Flaveny CA
Sci Rep; 2019 Dec; 9(1):19530. PubMed ID: 31863071
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin Induces Pyroptosis via Activation of MEG3/NLRP3/caspase-1/GSDMD Pathway in Triple-Negative Breast Cancer.
Yan H; Luo B; Wu X; Guan F; Yu X; Zhao L; Ke X; Wu J; Yuan J
Int J Biol Sci; 2021; 17(10):2606-2621. PubMed ID: 34326697
[TBL] [Abstract][Full Text] [Related]
10. Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer.
Qiu X; Qu Y; Guo B; Zheng H; Meng F; Zhong Z
J Control Release; 2022 Jan; 341():498-510. PubMed ID: 34883139
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of antitumor function of tumor-infiltrating lymphocytes against triple-negative breast cancer by PD-1 blockade.
Song H; Wang H; Gong M; Wu L; Liu X; Cao W; Gao X; Dou R; Chen Q; Hu H
Cell Biol Int; 2022 Feb; 46(2):278-287. PubMed ID: 34854515
[TBL] [Abstract][Full Text] [Related]
12. Immunological therapy: A novel thriving area for triple-negative breast cancer treatment.
Wang X; Qi Y; Kong X; Zhai J; Li Y; Song Y; Wang J; Feng X; Fang Y
Cancer Lett; 2019 Feb; 442():409-428. PubMed ID: 30419345
[TBL] [Abstract][Full Text] [Related]
13. Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.
Kwilas AR; Ardiani A; Gameiro SR; Richards J; Hall AB; Hodge JW
Oncotarget; 2016 Apr; 7(17):23498-511. PubMed ID: 27015557
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
15. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer.
Wei H; Wang Z; Kuang Y; Wu Z; Zhao S; Zhang Z; Li H; Zheng M; Zhang N; Long C; Guo W; Nie C; Yang H; Tong A
Front Immunol; 2020; 11():573823. PubMed ID: 33072116
[TBL] [Abstract][Full Text] [Related]
16. Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer.
Liu H; Bai L; Huang L; Ning N; Li L; Li Y; Dong X; Du Q; Xia M; Chen Y; Zhao L; Li Y; Meng Q; Wang J; Duan Y; Ming J; Yuan AQ; Yang XP
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599021
[TBL] [Abstract][Full Text] [Related]
17. CXorf61 is a target for T cell based immunotherapy of triple-negative breast cancer.
Paret C; Simon P; Vormbrock K; Bender C; Kölsch A; Breitkreuz A; Yildiz Ö; Omokoko T; Hubich-Rau S; Hartmann C; Häcker S; Wagner M; Roldan DB; Selmi A; Türeci Ö; Sahin U
Oncotarget; 2015 Sep; 6(28):25356-67. PubMed ID: 26327325
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of PD-1 and CD39 in tumor-infiltrating lymphocytes compared with peripheral blood lymphocytes in triple-negative breast cancer.
Zahran AM; Rayan A; Zahran ZAM; Mohamed WMY; Mohamed DO; Abdel-Rahim MH; El-Badawy O
PLoS One; 2022; 17(1):e0262650. PubMed ID: 35051220
[TBL] [Abstract][Full Text] [Related]
19. CELF2 is a candidate prognostic and immunotherapy biomarker in triple-negative breast cancer and lung squamous cell carcinoma: A pan-cancer analysis.
Wang L; Liu Z; Liu L; Guo C; Jiao D; Li L; Zhao J; Han X; Sun Y
J Cell Mol Med; 2021 Aug; 25(15):7559-7574. PubMed ID: 34288370
[TBL] [Abstract][Full Text] [Related]
20. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
